A Cochrane review [Abstract] 1 on cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma included 14 studies, 8 of which compared 'more' with 'less' chemotherapy(n=1519). Treatment consisting of 'more' chemotherapy was associated with longer overall survival (OS) (hazard ratio (HR) 0.86; 95% confidence intervals (CI) 0.77 to 0.96; P = 0.005) and with longer progression-free survival (PFS) ( HR 0.82; 95% CI 0.74 to 0.90; n = 1526, P < 0.0001). However, serious acute toxicities were more common in women randomised to the more-intense chemotherapy regimens.
There was no evidence to suggest that any particular doublet chemotherapy was better (or worse) than any other, or that any single-agent chemotherapy was better (or worse) than another; however, data for these two comparisons were limited. There were no comparative trials of chemotherapy with endocrine therapy or best supportive care alone.
Primary/Secondary Keywords